Concepedia

Author

Alice Ke

Simcyp (United Kingdom)ORCID

Also Known As

A B Ke, A Ke, A. Ke, Alice B Ke, Alice B. Ke, Alice Ban Ke, Alice Ke

41

Publications

1.2K

Citations

17

H-Index

29

Concepts

All Affiliations

Simcyp (United Kingdom)Eli Lilly (United States)Certara (United States)Center for Drug Evaluation and ResearchIntegra LifeSciences (United States)
AK

About

Alice Ke is an author at Simcyp (United Kingdom) specializing in medicine, pharmacokinetics, and pharmacokinetic modeling.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

91

2

Pharmacology

5

5

91

3

Health Sciences

1

1

11

4

Natural Sciences

1

1

11

5

Biochemistry

1

1

11

Alice Ke

×

20

Publications

740

Citations

15

H-Index

YearCitations

Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19

Alice Ke, Srikanth C. Nallani, Ping Zhao,

British Journal of Clinical Pharmacology

2013

109

Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein

J. William Higgins, Jing Bao, Alice Ke,

Drug Metabolism and Disposition

2013

92

A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women

Alice Ke, Srikanth C. Nallani, Ping Zhao,

Drug Metabolism and Disposition

2013

86

Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies

Alice Ke, M J Zamek-Gliszczynski, J. William Higgins,

Clinical Pharmacology & Therapeutics

2014

57

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Alice Ke, Zoe Barter, K Rowland‐Yeo,

CPT Pharmacometrics & Systems Pharmacology

2016

49

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling

Karen Rowland Yeo, Mian Zhang, Xian Pan,

Clinical Pharmacology & Therapeutics

2020

40

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

Jayaprakasam Bolleddula, Alice Ke, Hua Yang,

CPT Pharmacometrics & Systems Pharmacology

2021

38

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

Peter Kilford, Kuan‐Fu Chen, Kim Crewe,

CPT Pharmacometrics & Systems Pharmacology

2022

38

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

Neeraj Gupta, Michael J. Hanley, Karthik Venkatakrishnan,

The Journal of Clinical Pharmacology

2017

37

Evaluation of Maternal Drug Exposure Following the Administration of Antenatal Corticosteroids During Late Pregnancy Using Physiologically‐Based Pharmacokinetic Modeling

Alice Ke, Mark A. Milad

Clinical Pharmacology & Therapeutics

2019

36

Page 1